LabDAO is a technology company.
LabDAO has raised $4.0M across 1 funding round.
LabDAO has raised $4.0M in total across 1 funding round.
LabDAO has raised $4.0M in total across 1 funding round.
LabDAO's investors include Collider Ventures, Divergence Ventures, Team8, Nimrod Lehavi.
LabDAO is a decentralized autonomous organization (DAO), not a traditional technology company, focused on advancing open-source drug discovery and life science research through shared computational tools and resources. It operates as a community-driven platform in the DeSci (decentralized science) space, providing scientists and engineers access to BioML (Biological Machine Learning) tools via its PLEX software hub, which enables command-line execution of data analyses, modeling, and experimental processing without institutional infrastructure[1][2][4]. LabDAO serves independent researchers, particularly in resource-limited settings, solving barriers to advanced tools, funding, and collaboration by leveraging blockchain for peer-to-peer resource sharing and data ownership via NFTs[1][2]. It raised $3.6M in seed funding in May 2023 from investors like Village Global, North Island Ventures, and Gnosis VC, showing early growth momentum in the Web3-bio intersection[3][4].
LabDAO was founded in 2022 by Niklas Rindtorff, a former MIT researcher in computational biology, alongside an international team of scientists, technologists, and open science advocates skilled in blockchain[1][4]. The idea emerged from Rindtorff's vision to democratize scientific research by bypassing traditional academic hierarchies, inspired by DeSci principles to make tools accessible globally[1]. Early traction came via its open-source BioML suite and the launch of PLEX, a containerized software hub streamlining access to computational biology tools, with plans to expand to physical lab resources; this built on seed funding in 2023, marking a pivotal shift toward practical DeSci infrastructure[1][2][3].
LabDAO rides the DeSci and bio-Web3 trend, merging blockchain with life sciences to counter centralized research limitations amid rising AI-driven drug discovery demands[1][4]. Timing aligns with explosive growth in computational biology tools post-2022 crypto winter, fueled by AI models like BioML and open-source movements challenging Big Pharma's IP dominance[2][4]. Market forces favoring it include surging demand for accessible AI in biotech (e.g., enzyme design speedups noted in related news) and DAO funding resurgence, positioning LabDAO to influence the ecosystem by onboarding global talent and scaling open drug discovery pipelines[1][4].
LabDAO's trajectory points to PLEX expansion into physical labs and deeper BioML integrations, potentially capturing a slice of the $100B+ drug discovery market through community-scaled open-source models. Trends like AI-bio convergence and regulatory nods to DeSci will propel it, evolving its influence from tool provider to ecosystem orchestrator—much like how it began by lowering barriers for one MIT researcher, now empowering thousands in decentralized science[1][2].
LabDAO has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in May 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2023 | $4.0M Seed | Collider Ventures, Divergence Ventures, Team8, Nimrod Lehavi |